# A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07362459/  
OnCo record `nct07362459` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing SCTB14 in non-small-cell lung cancer, now recruiting.

## Summary

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07362459, led by Sinocelltech, and recruiting on the registry. Official title: A Phase III, Randomised, Double-blind, Multicenter Clinical Study to Evaluate the Efficacy and Safety of SCTB14 Versus Pembrolizumab as First-Line Therapy in Patients With Driver Gene-Negative, TPS ≥10% Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Planned enrolment is 246 participants (estimated). The study started in 2025-12-30 and primary completion is expected in 2027-07. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07362459
- Phase: 3
- Setting: A Phase III, Randomized, Double-blind, Multicenter Clinical Study to Evaluate the Efficacy and Safety of SCTB14 Versus Pembrolizumab as First-Line Therapy in Patients With Driver Gene-Negative, TPS ≥10% Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Sinocelltech
- Enrolled: 246

## Sources

- ClinicalTrials.gov NCT07362459: https://clinicaltrials.gov/study/NCT07362459

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [SCTB14](https://onco.cc/drugs/sctb14/)
- companies: [Sinocelltech](https://onco.cc/companies/sinocelltech/)

---
JSON: https://onco.cc/api/v1/entities/nct07362459.json